STAT

DECEMBER 30, 2024

Although bipartisan legislation to provide Medicare coverage for obesity treatments has circulated in Congress for more than a decade, the Congressional Budget Office (CBO) ventured to  estimate  the budgetary effects of such a policy for older Americans starting in 2026 for the very first time in a report published in October. 

141

141

Fierce Healthcare

DECEMBER 6, 2022

CMS proposes certain payers implement electronic prior authorization systems by 2026. Tue, 12/06/2022 - 17:04.

109

109

Fierce Healthcare

JUNE 2, 2025

HIV and cancer prevention advocates are among the groups worried over cuts to critical programs at HHS under a new fiscal year 2026 budget request.

79

79

European Pharmaceutical Review

SEPTEMBER 12, 2023

Over 50 percent of respondents answered that machine learning for optimisation of manufacturing processes will be the technology that will be used routinely in the pharmaceutical industry by 2026. The post AI to revolutionise drug development by 2026 appeared first on European Pharmaceutical Review.

FDA 105

FDA Pharmaceutical Companies Pharmaceutical Companies 105

Fierce Pharma

MAY 6, 2024

With plans to have at least 10 potentially registrational trials underway by the end of 2024, BioNTech is plotting the first wave of its market debut in oncology from 2026 onward. As BioNTech continues to endure a sharp decline in COVID-19 vaccine sales, the German mRNA specialist is looking ahead to the next leg of its commercial journey.

Vaccines 118

Vaccines 118

European Pharmaceutical Review

AUGUST 19, 2022

billion by 2026. percent between 2021 and 2026 (the forecast period). Billion by 2026, achieving a 5.6 billion by 2026, as contract manufacturing organisations increasingly adopt newer and efficient ways to package products, increasing demand for new machinery. billion by the year 2026. Within the $130.2

Packaging 98

Packaging Compounding 98

STAT

MAY 1, 2025

CVS Health will not sell its Aetna health plans in the Affordable Care Act’s individual marketplaces in 2026, marking the second time in the past decade that Aetna has given up on ACA coverage. CVS expects to lose up to $400 million this year in its ACA plans.

Insurance 136

Insurance 136

STAT

OCTOBER 29, 2024

billion in estimated out-of-pocket savings for people with Medicare prescription drug coverage when the negotiated prices are set to go into effect in 2026.

124

124

Pharmacy Times

APRIL 2, 2025

The only major change is in the included strain of influenza A/H2N2 virus, which has been updated for both the egg-based and the cell- and recombinant-based vaccines.

Vaccines 122

Vaccines 122

PharmaVoice

MARCH 11, 2025

Emalex Biosciences is full steam ahead with a targeted 2026 approval and launch for its novel drug.

179

179

Fierce Pharma

MARCH 30, 2023

Pfizer, BMS' Eliquis tops list of drugs destined for Medicare price negotiations in 2026: Moody's kdunleavy Thu, 03/30/2023 - 07:28

79

79

STAT

JANUARY 29, 2025

Curie.Bio’s new fund will help the organization double its investing over the next two years: The aim is to invest in between 15 and 20 biotechs this year and up to 25 companies in 2026, the founders told STAT exclusively. Continue to STAT+ to read the full story…

101

101

Pharmacy Times

AUGUST 15, 2024

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

149

149

PharmaVoice

AUGUST 16, 2024

The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.

147

147

Fierce Healthcare

MARCH 15, 2023

CMS gives an early look at how it plans to negotiate Part D drug prices in 2026 dmuoio Wed, 03/15/2023 - 17:35

73

73

Fierce Healthcare

OCTOBER 4, 2024

A proposed rule from the Centers for Medicare & Medicaid Services (CMS) released Oct. | CMS is looking to shake up the risk adjustment model and wants the ability to suspend shady brokers from the insurance marketplace, the agency wrote among other updates in a new proposed rule.

Insurance 104

Insurance 104

PharmaVoice

NOVEMBER 5, 2024

Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.

130

130

Pharmaceutical Technology

NOVEMBER 19, 2024

Regenxbio’s plans toward a BLA filing in 2026 after positive data from the Phase I/II AFINITY DUCHENNE trial.

52

52

Pharmacy Times

AUGUST 30, 2023

Any new prices established after negotiations will be effective on January 1, 2026.

132

132

STAT

SEPTEMBER 6, 2023

29, Medicare released its highly anticipated list of 10 therapies for which it plans to establish a price by 2026.

135

135

Mission-Driven Marketing Blog

NOVEMBER 1, 2023

Communities of Excellence 2026 (COE) announces strategic partnerships with TAPP Network and PMG Consulting, to improve the quality of life for our nation.

52

52

The FDA Law Blog

JANUARY 18, 2023

The memorandum outlines CMS’s priorities and timeline for the Initial Price Applicability Year 2026. The topics focus on issues relevant in the first three years of the Negotiation Program—2026 to 2028. Finally, the memorandum has a handy timeline of the key dates associated with the Initial Price Applicability Year 2026.

Dosage 59

Dosage 59

Outsourcing Pharma

SEPTEMBER 17, 2024

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal infections in 2026.

FDA 110

FDA 110

Fierce Pharma

OCTOBER 30, 2024

Ever since the FDA rejected zuranolone in major depressive disorder last year, brai | In the wake of a recent round of layoffs, the company this week revealed that it’s discontinuing a commercial medicine and giving up hopes for a pair of pipeline prospects.

FDA 85

FDA 85

STAT

AUGUST 13, 2024

In a press release, the company said that the cuts would help it extend its cash reserves from the second half of 2026 into 2028. The Bay Area biotech brought in $32 million during the quarter but also reported a net loss of $1.6 Continue to STAT+ to read the full story…

143

143

pharmaphorum

MAY 3, 2024

AI-powered home healthcare model from Cera could save NHS and UK £1bn in 2026 if adopted nationwide, says new study

108

108

Fierce Pharma

SEPTEMBER 7, 2023

Now that the Centers for Medicare & Medicaid Services (CMS) has revealed its li | Now that the CMS has revealed its list of the first 10 drugs subject to Medicare price negotiations under the Inflation Reduction Act, it’s time to consider the financial implications for affected companies.

82

82

STAT

OCTOBER 9, 2024

The Congressional Budget Office estimates that 29 million beneficiaries would qualify for weight loss drugs in 2026.    Drugs for those conditions already exist, and they’re often generic. But a lot of people are switching to GLP-1s.   Continue to STAT+ to read the full story…

135

135

STAT

SEPTEMBER 23, 2024

Though the DEA is currently contemplating new regulations that would roll back many of the pandemic-era flexibilities, the lawmakers’ new bill would likely extend the current rules through 2026, according to two lobbyists familiar with the effort.  

Controlled Substances 134

Controlled Substances 134

Pharmaceutical Commerce

AUGUST 16, 2024

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

98

98

Outsourcing Pharma

OCTOBER 3, 2024

The proceeds of the financing will support the development of LoQus23âs lead candidate, a small molecule inhibitor that is expected to enter the clinic in 2026.

94

94

STAT

SEPTEMBER 20, 2024

The new guidance will affect nearly 6,000 universities and other institutions with projects funded by HHS, which have until 2026 to comply.

136

136

STAT

FEBRUARY 14, 2025

trillion between 2026 and 2035. There is a lot of pressure to make big cuts to government spending. The Treasury Department estimates that renewing the expiring individual and estate tax provisions would cost $4.2 A group of nine Senate Republicans, including Majority Leader John Thune (S.D.)

136

136

STAT

FEBRUARY 1, 2024

  The negotiated prices won’t take effect until 2026.  The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends.    Continue to STAT+ to read the full story…

Pharmaceutical Companies 130

Pharmaceutical Companies Pharmaceutical Companies 130

Pharmaceutical Technology

FEBRUARY 6, 2025

CagriSema, considered a successor to Wegovy, is Novo Nordisks most likely route of gaining GLP-1RA market share back from Eli Lilly.

64

64

STAT

APRIL 16, 2024

It would carve grocers, restaurants, and food warehouses out of a major portion of the FDA’s rules, which are meant to help regulators quickly track down the cause of a foodborne outbreak, and it would delay enforcement of the entire food safety program, slated to begin in 2026, by several years.

FDA 142

FDA 142

STAT

SEPTEMBER 4, 2024

The sites are expected to employ another 90 people and open by 2026.  The pharmaceutical giant will spend more than $200 million to construct the new facility in Carlsbad, Calif., and expand its site in Indianapolis, representatives told STAT exclusively.

121

121